%0 Journal Article %A Makoto Koizumi %A Motoaki Utamura %A Seiichi Kirikami %T Infection spread simulation technology in a mixed state of multi variant viruses %D 2021 %R 10.1101/2021.06.28.21259679 %J medRxiv %P 2021.06.28.21259679 %X ATLM was extended to simulate the spread of infection in a mixed state of mutant virus and conventional virus. It is applied to the 4th wave of infection spread in Tokyo, and (1) the 4th wave bottoms out near the end of the state of emergency, and the number of infected people increases again. (2) The rate of increase will be mainly by L452R virus, while the increase by N501Y virus will be suppressed. (3) It is anticipated that the infection will spread during the Olympic Games. (4) When mutant virus competes, the infection of highly infectious virus rises sharply while the infection by weakly infectious ones has converged. (5) It is effective as an infection control measure to find an infected person early and shorten the period from infection to quarantine by PCR test or antigen test as a measure other than vaccine.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialnoneFunding StatementThis research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The authors declare that they have no conflict of interest related to this report or the study it describes.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe used time-series data of COVID-19 for March 1 through June 10, 2021 in Tokyo, which is publicly available. https://stopcovid19.metro.tokyo.lg.jp/en %U https://www.medrxiv.org/content/medrxiv/early/2021/07/06/2021.06.28.21259679.full.pdf